|
Click on the link of interest below to learn how EpiAirway tissues can help improve the reproducibility of your experimental procedures:
Overview
Drug Delivery
Pharmacology/Toxicology
Asthma, Smoker, COPD Research
Respiratory Infection
Nanotoxicology (new browser window will open)
Product Configurations - includes 24 & 96-well HTS
====================
Overview
MatTek's EpiAirway™ System is the only commercially available in vitro airway tissue model that originates from normal, human-derived tracheal/bronchial epithelial (NHBE) cells which have been cultured to form a 3-dimensional, pseudo-stratified, highly differentiated model closely resembling the epithelial tissue of the respiratory tract.
When choosing an airway tissue model on which to base one's research, it is very important to choose a model which originates from normal (non-immortalized) cells. Why? Cell lines typically exhibit several abnormal characteristics in addition to their immortality, and those abnormalities can impede drug studies. For example, certain airway cell lines have lost the ability to form tight junctions, thereby eliminating their ability to produce in vivo-like barrier properties. The A549 cell line is one that has been found to be "functionally deficient in tight junctions" in independent research.
It is equally important to choose a human cell-derived tissue model, in order to avoid the inevitable species-related differences that could compromise experimental results.
Finally, a highly differentiated, 3-dimensional model is desirable because it more closely mirrors true in vivo airway tissue. Drug interaction studies performed using a differentiated 3-D in vitro model will therefore more closely mimic human airway tissue interactions.
Click on the link of interest (below) to learn how the EpiAirway model can help improve the reproducibility of your experimental procedures:
Drug Delivery
Pharmacology/Toxicology
Asthma, Smoker, COPD Research
Respiratory Infection
Nanotoxicology (new browser window will open)
Product Configurations - includes 24 & 96-well HTS
====================
EpiAirway tissues have proven to be a highly reliable model for drug permeation of inhaled pharmaceutical formulations. Established protocols for measuring toxicity, transepithelial electrical resistance and drug permeation enable rapid pre-clinical optimization of candidate formulations.
IN VITRO FORMULATION OPTIMIZATION OF INTRANASAL GALANTAMINE LEADING TO ENHANCED BIOAVAILABILITY AND REDUCED EMETIC RESPONSE IN VIVO. (MatTek TR 508)
IN VITRO AND IN VIVO SCREENING OF INTRANASAL INSULIN FORMULATIONS. (MatTek TR 448)
PEPTIDES AND PEGYLATED PEPTIDES AS INTRANASAL PERMEATION ENHANCERS: COMPARISON TO SMALL MOLECULAR EXCIPIENTS. (MatTek TR 415)
FORMULATION DEVELOPMENT OF siRNAs FOR DRUG DELIVERY: A NEW THERAPEUTIC APPROACH FOR PANDEMIC INFLUENZA. (MatTek TR 414)
THERAPEUTIC UTILITY OF A NOVEL TIGHT JUNCTION MODULATING PEPTIDE FOR ENHANCING INTRANASAL DRUG DELIVERY. (MatTek TR 413)
PEPTIDE DRUG PERMEATION ENHANCEMENT BY SELECT CLASSES OF LIPIDS. (MatTek TR 391)
DEVELOPMENT OF A NOVEL HIGH-CONCENTRATION GALANTAMINE FORMULATION SUITABLE FOR INTRANASAL DELIVERY. (MatTek TR 390)
INTRANASAL DELIVERY OF RECOMBINANT HUMAN PARATHYROID HORMONE [HPTH (1–34)], TERIPARATIDE IN RATS. (MatTek TR 368)
CANNABIDIOL DIFFUSION ACROSS HUMAN TRACHEO-BRONCHIAL TISSUE (EPIAIRWAY™) AND INTRANASAL ABSORPTION IN RATS. (MatTek TR 334)
PERMEATION OF WIN 55,212-2, A POTENT CANNABINOID RECEPTOR AGONIST, ACROSS HUMAN TRACHEO-BRONCHIAL TISSUE (EPIAIRWAY™) IN VITRO AND RAT NASAL EPITHELIUM IN VIVO. (MatTek TR 331)
DRUG PERMEABILITY ACROSS BOVINE RESPIRATORY TISSUES COMPARED TO A HUMAN TRACHEO/BRONCHIAL CELL CULTURE (EPIAIRWAY™ SYSTEM). (MatTek TR 315)
DOPAMINE TRANSPORT ACROSS RESPIRATORY EPITHELIUM.). (MatTek TR 314)
DEVELOPMENT OF AN INTRANASAL FORMULATION OF THE Y2R AGONIST PEPTIDE YY3-36. (MatTek TR 310)
EFFECTS OF ENHANCERS ON MACROMOLECULES FORMULATIONS ON MEMBRANE PENETRATION, CELL VIABILITY AND RESISTANCE USING EPI-AIRWAYS™ TISSUE MODEL. (MatTek TR 244)
PERMEABILITY AND CYTOTOXICITY OF MACROMOLECULE FROM NASAL FORMULATION USING EPIAIRWAY TISSUE MODEL. (MatTek TR 243)
There has also been nasal drug delivery research performed using the EpiAirway model at a major U.S. university (SUNY Stony Brook, NY). A summary and a poster (in PDF format) of that research are available below with the author's permission:
REPRODUCIBILITY OF EPIAIRWAY™, A DIFFERENTIATED AIRWAY TISSUE MODEL FOR PRE-CLINICAL DRUG DEVELOPMENT STUDIES. (MatTek TR 298)
EVALUATION OF THE PENETRATION AND CYTOTOXIC EFFECTS OF DRUG FORMULATIONS ON AN IN VITRO NASAL MUCOSAL MODEL
AN IN VITRO MODEL FOR THE RAPID SCREENING OF POTENTIAL COMPONENTS AND FORMULATIONS FOR NASAL DRUG DELIVERY (MatTek TR 271)
EpiAirway tissues are ideal for basic cell and molecular biology studies, pharmaceutical target validation and pre-clinical toxicity/efficacy determination, as well as inhalation toxicity studies of occupational or environmental air pollutants and toxins.
Examples of common uses include regulation of transepithelial electrical resistance, inflammatory mediator secretion, tissue viability, protein and gene regulation and mucin regulation.
IDENTIFICATION OF INTELLIGENT BIOMARKERS OF EXPOSURE AND HARM IN THE RESPIRATORY EPITHELIAL TO TOBACCO SMOKE COMPONENTS. (MatTek TR 359)
TUMOR NECROSIS FACTOR ALPHA (TNFα) INDUCTION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) EXPRESSION IS MEDIATED BY 15-LIPOXYGENASE 15-(LOX)-2 IN THE EPIAIRWAY™ HUMAN TRACHEAL/BRONCHIAL EPITHELIAL MODEL. (MatTek TR 267)
EXPRESSION OF 15-LIPOXYGENASE-2 IN THE EPIAIRWAY™ IN VITRO HUMAN TRACHEAL/BRONCHIAL EPITHELIAL MODEL: REGULATION BY TNF-α AND INF-γ. (MatTek TR 256)
CHARACTERIZATION OF INFLAMMATORY MEDIATOR RELEASE FROM AN IN VITRO HUMAN TRACHEAL/BRONCHIAL EPITHELIAL TISSUE MODEL. (MatTek TR 242)
OVERVIEW - OCCUPATIONAL/ENVIRONMENTAL AIR POLLUTANTS AND TOXINS STUDIES
Non-Standard EpiAirway tissues produced from ASTHMATIC, SMOKER and COPD donor cells are available for research use. Please call the EpiAirway Lead Scientist for technical details, pricing and availability.
Listing of Asthma-related Technical References
Listing of COPD-related Technical References
Listing of Smoking/Tobacco-related Technical References
EpiAirway tissues also have proven utility as models for the study of respiratory infection and pre-clinical antibiotic development.
HUMAN PARAINFLUENZA VIRUS INFECTION OF THE AIRWAY EPITHELIUM: THE VIRAL HEMAGGLUTININ-NEURAMINIDASE REGULATES FUSION PROTEIN ACTIVATION AND MODULATES INFECTIVITY. (MatTek TR 516)
FORMULATION DEVELOPMENT OF siRNAs FOR DRUG DELIVERY: A NEW THERAPEUTIC APPROACH FOR PANDEMIC INFLUENZA. (MatTek TR 414)
RECONSTRUCTED, DIFFERENTIATED AIRWAY EPITHELIAL CULTURES TO MODEL RESPIRATORY INFECTION. (MatTek TR 156)
====================
Product Configurations
EpiAirway cultures are available in standard 9 mm (inner) diameter inserts (AIR-100, AIR-100-Asthma), Corning Costar Snapwell™ inserts (AIR-100-SNP, AIR-100-Asthma-SNP) that fit into perfusion chambers specifically designed to accept Snapwell inserts, Transwell inserts for the VITROCELL apparatus, and 24-well and 96-microwell High Throughput Screening (HTS) configurations (AIR-124-HTS, AIR-196-HTS).
Snapwell inserts are also ideally suited for gaseous exposures (inhalation toxicology studies) when mounted into special perfusion chambers designed to isolate the basolateral compartment from the apical surface. This configuration allows exposure of the apical surface while preventing gaseous materials from direct contact with the perfusion medium. Examples of these special perfusion chambers include the Ussing Diffusion Chamber Systems sold by Harvard Apparatus.
=================
EpiAirway Data Sheet
EpiAirway Product Specifications
EpiAirway Technical References
|
